Kurzfassung

a randomized, double-blind, placebo-controlled Phase 1b/2 study of LY2228820, a p38 MAPK Inhibitor, plus Gemcitabine and Carboplatin versus Gemcitabine and Carboplatin fpr women with Platinum-sensitive Ovarian Cancer